Home » Authors » Anette Breindl

Articles by Anette Breindl

Effects Impressive, Mechanism Elusive For Endocannabinoids

Nov. 1, 2004

By Anette Breindl

Effects Impressive, Mechanism Elusive For Endocannabinoids

Nov. 1, 2004

By Anette Breindl

Although Vioxx Troubled, Cox-2 Area Still Of Interest

Oct. 28, 2004

By Anette Breindl

Although Vioxx Troubled, Cox-2 Area Still Of Interest

Oct. 28, 2004

By Anette Breindl

Retrotransposons: 'Junk' DNA? No, Instead Alternate Promoters

Oct. 26, 2004

By Anette Breindl

Combination Agent Showing Antitumor Effects Flying Solo

Oct. 25, 2004

By Anette Breindl

Combination Agent Showing Antitumor Effects Flying Solo

Oct. 25, 2004

By Anette Breindl

Adenosine Receptors Linked To Stroke-Induced Brain Damage

Oct. 20, 2004

By Anette Breindl

Adenosine Receptors Linked To Stroke-Induced Brain Damage

Oct. 20, 2004

By Anette Breindl

Cord Blood Cells In Stroke Model Triumph Over Blood-Brain Barrier

Oct. 19, 2004

By Anette Breindl

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 10, 2025
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...
Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology
BioWorld
About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...